SG11201507519RA - Pyrazolonaphthyridinone derivatives as metap2 inhibitors (methionine aminopeptidase type-2) - Google Patents

Pyrazolonaphthyridinone derivatives as metap2 inhibitors (methionine aminopeptidase type-2)

Info

Publication number
SG11201507519RA
SG11201507519RA SG11201507519RA SG11201507519RA SG11201507519RA SG 11201507519R A SG11201507519R A SG 11201507519RA SG 11201507519R A SG11201507519R A SG 11201507519RA SG 11201507519R A SG11201507519R A SG 11201507519RA SG 11201507519R A SG11201507519R A SG 11201507519RA
Authority
SG
Singapore
Prior art keywords
pyrazolonaphthyridinone
derivatives
methionine aminopeptidase
metap2 inhibitors
aminopeptidase type
Prior art date
Application number
SG11201507519RA
Other languages
English (en)
Inventor
Nathalie Guillo
Valérie Martin
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG11201507519RA publication Critical patent/SG11201507519RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/04Esters of boric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
SG11201507519RA 2013-03-25 2014-03-21 Pyrazolonaphthyridinone derivatives as metap2 inhibitors (methionine aminopeptidase type-2) SG11201507519RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13305365 2013-03-25
PCT/EP2014/055719 WO2014154586A1 (en) 2013-03-25 2014-03-21 Pyrazolonaphthyridinone derivatives as metap2 inhibitors (methionine aminopeptidase type-2)

Publications (1)

Publication Number Publication Date
SG11201507519RA true SG11201507519RA (en) 2015-10-29

Family

ID=48040135

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201507519RA SG11201507519RA (en) 2013-03-25 2014-03-21 Pyrazolonaphthyridinone derivatives as metap2 inhibitors (methionine aminopeptidase type-2)

Country Status (17)

Country Link
US (1) US9856257B2 (pl)
EP (1) EP2978764B1 (pl)
JP (1) JP2016515541A (pl)
KR (1) KR20150135406A (pl)
CN (1) CN105246893B (pl)
AU (1) AU2014243257A1 (pl)
BR (1) BR112015024189A2 (pl)
CA (1) CA2907532A1 (pl)
DK (1) DK2978764T3 (pl)
ES (1) ES2633440T3 (pl)
IL (1) IL241447A0 (pl)
MX (1) MX2015013740A (pl)
PL (1) PL2978764T3 (pl)
PT (1) PT2978764T (pl)
RU (1) RU2015145479A (pl)
SG (1) SG11201507519RA (pl)
WO (1) WO2014154586A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201406486D0 (en) * 2014-04-10 2014-05-28 Redx Pharma Ltd Antibacterial compounds
US10105349B2 (en) * 2014-12-06 2018-10-23 Intra-Cellular Therapies, Inc. Organic compounds
KR102557603B1 (ko) 2014-12-06 2023-07-19 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2017046606A1 (en) * 2015-09-18 2017-03-23 Redx Pharma Plc Antibacterial compounds
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有mgat2抑制活性的縮合環衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080046728A (ko) * 2005-09-15 2008-05-27 아스카 세이야쿠 가부시키가이샤 복소환 화합물, 그의 제조 방법 및 용도
AR068063A1 (es) * 2007-08-27 2009-11-04 Basf Plant Science Gmbh Co mpuestos de pirazol para controlar plagas de invertebrados
JP5941981B2 (ja) 2011-05-06 2016-06-29 ザフゲン,インコーポレイテッド 三環式スルホンアミド化合物ならびにその製造および使用方法
US9169246B2 (en) 2011-09-26 2015-10-27 Sanofi Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
US20140235616A1 (en) 2011-09-26 2014-08-21 Sanofi Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
EP2573073B1 (en) * 2011-09-26 2014-10-22 Sanofi Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof

Also Published As

Publication number Publication date
PT2978764T (pt) 2017-07-17
IL241447A0 (en) 2015-11-30
JP2016515541A (ja) 2016-05-30
BR112015024189A2 (pt) 2017-07-18
CA2907532A1 (en) 2014-10-02
EP2978764B1 (en) 2017-04-19
MX2015013740A (es) 2016-02-29
WO2014154586A1 (en) 2014-10-02
DK2978764T3 (en) 2017-07-31
CN105246893B (zh) 2017-10-27
ES2633440T3 (es) 2017-09-21
AU2014243257A1 (en) 2015-10-15
EP2978764A1 (en) 2016-02-03
PL2978764T3 (pl) 2017-09-29
US20160060265A1 (en) 2016-03-03
KR20150135406A (ko) 2015-12-02
CN105246893A (zh) 2016-01-13
US9856257B2 (en) 2018-01-02
RU2015145479A (ru) 2017-05-02

Similar Documents

Publication Publication Date Title
HK1221466A1 (zh) 作為 抑制劑的聯吡唑衍生物
AR095266A1 (es) Inhibidores de bromodominios tetraciclicos
HK1219475A1 (zh) 腦啡肽酶抑制劑
HK1216531A1 (zh) 新的抑制劑
GB201317609D0 (en) Inhibitor compounds
EP2991654A4 (en) NOVEL CONNECTIONS AS AN ERK HEMMER
HK1222339A1 (zh) 金屬-β-內酰胺酶的抑制劑
EP2961403A4 (en) HETEROCYCLIC INHIBITORS OF SODIUM CHANNEL
IL241447A0 (en) Pyrazolonenaphthyridinone derivatives as 2metap (methionine aminopeptidase type 2) inhibitors
IL244029B (en) Deoxycytodine kinase inhibitors
HK1222582A1 (zh) 用於改善膀胱尿道協同失調的藥劑
DOS2014000147S (es) Envases / (parte de)
UA31214S (uk) Упаковка для сигарет
GB201321328D0 (en) Inhibitor compounds
UA31604S (uk) Упаковка для сигарет
UA29169S (uk) Упаковка для сигарет
GB201305503D0 (en) Inhibitor